**SciTech Presentation and Interview at NIBA Investment Conference in New York City**

[](https://www.youtube.com/embed/Aa65iJCv3TU)

**YouTube URL:** <https://www.youtube.com/embed/Aa65iJCv3TU>

**Description:** SciTech Development presentation at the National Investment Banking Association (NIBA) conference in New York City. For more info visit http://www.scitechdevelopment.com Earle Holsapple, President of SciTech, presents to investment bankers: introducing SciTech's patented ST-001 nanoFenretinide technology (nanoparticle sized fenretinide in a phospholipid matrix) for the treatment of several types of cancer including T-cell non-Hodgkin's lymphoma (T-cell NHL) and small cell lung cancer (SCLC) as well as the broad therapeutic reach of nanoFenretinide; investing and partnering opportunities. NIBA representatives interview Earle Holsapple at the event.

**Video Transcript:**

[Music]

Hello, I'm Earl Holsapple I'm the founder and president of a biopharmaceutical development company named SciTech. We have enabled an oncology drug that has been in a class of drugs that have been studied for years in the treatment of a broad cross-section of cancers. We're here at this event to introduce it to NIBA. We're excited about talking with the investment banking community as a possible way to fund our ongoing development operations and we're pleased to be here.

[Music]

What brings you to the NIBA Conference?

So we're at work, we're trying to be introduced to investment bankers that will help us raise the initial five million dollars required to complete a Phase one, sort of combination Phase two, delivery or a clinical trial to reconfirm the safety and efficacy of this drug in its new format and in essence enable it to be used in other cancer indications

[Music]

Can you tell us about the management team? We've got quite an interesting management team coming from every discipline in the field; so, our inventor is a senior manager at the National Cancer Institute now and runs most of the laboratory operations; we have our Chief Medical Officer who's a former Cancer Center Director and brings lymphoma cancer and clinical trial experience to bear. I've been the CEO of several startups including one that is resulted in a new breast cancer detection technology that's moving into the marketplace as we speak. As importantly, we have an outside group of advisers who bring the commercial, scientific and clinical perspective from some of the finest organizations in the world to bear to help us bring this product forward.

[Music]

Can you tell us any recent news? Well the recent news is that we're about to file our application with the Food and Drug Administration to test this drug in humans. It's called an IND application and we'll be submitting it in the next couple of days it's a major accomplishment for us; secondly, there's new scientific data that suggests that the drug fenretinide that we're enabling has an immune response that hadn't been seen before. It has been shown that in the treatment of lymphoma cancer, it actually results in a reengagement or a reactivation of the immune system that has been damaged by the cancer cells; so, it takes our product into a whole new category of development opportunities by considering it as a possible immune therapy along with a therapy that just causes cell death for cancer cells

[Music]

Where can we find more info?

Well thank you for watching and I hope you want to learn more about us you can go to our website scitechdevelopment.com or you can contact me through the website, the contact information is there. We would love to talk to you about an investment in this opportunity. We think that it has great potential, thank you.

[](https://www.scitechdevelopment.com/the-product)***For investment and partnering opportunities contact Earle Holsapple | (313) 263-4887 |*** [***eth@scitechdevelopment.com***](mailto:eth@scitechdevelopment.com)